View Filing Data

Print Document View Excel Document

Document And Entity Information - shares	6 Months Ended
Document And Entity Information - shares	Jun. 30, 2018	Aug. 02, 2018
Document Information [Line Items]
Document Type	10-Q
Amendment Flag	false
Document Period End Date	Jun. 30, 2018
Document Fiscal Year Focus	2018
Document Fiscal Period Focus	Q2
Entity Registrant Name	TAPIMMUNE INC.
Entity Central Index Key	0001094038
Current Fiscal Year End Date	--12-31
Entity Filer Category	Smaller Reporting Company
Trading Symbol	TPIV
Entity Common Stock, Shares Outstanding		13,710,544

CONDENSED CONSOLIDATED BALANCE SHEETS - USD ($)	Jun. 30, 2018	Dec. 31, 2017
Current assets:
Cash	$ 7,782,962	$ 5,129,289
Prepaid expenses and deposits	108,716	51,150
Total current assets	7,891,678	5,180,439
Total assets	7,891,678	5,180,439
Current liabilities:
Accounts payable and accrued liabilities	3,595,152	1,508,312
Warrant liability	147,000	9,000
Promissory note	5,000	5,000
Total current liabilities	3,747,152	1,522,312
Total liabilities	3,747,152	1,522,312
COMMITMENTS AND CONTINGENCIES
Stockholders' equity:
Common stock, $0.001 par value, 41.7 million shares authorized, 13.6 million and 10.6 million shares issued and outstanding as of June 30, 2018 and December 31, 2017, respectively	13,624	10,616
Additional paid-in capital	170,287,725	161,067,538
Accumulated deficit	(166,156,823)	(157,420,027)
Total stockholders' equity	4,144,526	3,658,127
Total liabilities and stockholders' equity	7,891,678	5,180,439
Series A Preferred Stock [Member]
Stockholders' equity:
Preferred Stock, Value	0	0
Series B Preferred Stock [Member]
Stockholders' equity:
Preferred Stock, Value	$ 0	$ 0

CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical) - $ / shares	Jun. 30, 2018	Dec. 31, 2017
Preferred stock par value	$ 0.001	$ 0.001
Preferred stock shares authorized/designated	5,000,000	5,000,000
Common stock shares par value	$ 0.001	$ 0.001
Common stock shares authorized	41,700,000	41,700,000
Common stock shares issued	13,600,000	10,600,000
Common stock shares outstanding	13,600,000	10,600,000
Series A Preferred Stock [Member]
Preferred stock par value	$ 0.001	$ 0.001
Preferred stock shares authorized/designated	1,250,000	1,250,000
Preferred stock issued	0	0
Preferred stock outstanding	0	0
Series B Preferred Stock [Member]
Preferred stock par value	$ 0.001	$ 0.001
Preferred stock shares authorized/designated	1,500,000	1,500,000
Preferred stock issued	0	0
Preferred stock outstanding	0	0

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($)	3 Months Ended		6 Months Ended
	Jun. 30, 2018	Jun. 30, 2017	Jun. 30, 2018	Jun. 30, 2017
Revenues:
Total revenues	$ 205,994	$ 0	$ 205,994	$ 0
Operating expenses:
Research and development	1,826,837	1,202,725	3,426,387	2,191,817
General and administrative	3,052,954	1,190,517	4,650,890	2,618,310
Total operating expenses	4,879,791	2,393,242	8,077,277	4,810,127
Loss from operations	(4,673,797)	(2,393,242)	(7,871,283)	(4,810,127)
Other income (expense):
Change in fair value of warrant liabilities	(139,000)	7,500	(138,000)	4,500
Debt extinguishment gain	0	492,365	0	492,365
Net loss	$ (4,812,797)	$ (1,893,377)	$ (8,009,283)	$ (4,313,262)
Net loss per share, Basic and Diluted	$ (0.41)	$ (0.22)	$ (0.71)	$ (0.51)
Weighted average number of common shares outstanding	11,838,371	8,576,634	11,233,755	8,503,521
Grant [Member]
Revenues:
Grant income	$ 205,994	$ 0	$ 205,994	$ 0

CONDENSED CONSOLIDATED STATEMENT OF STOCKHOLDERS' EQUITY - 6 months ended Jun. 30, 2018 - USD ($)	Total	Common Stock [Member]	Additional Paid In Capital [Member]	Accumulated Deficit [Member]
Balance, Amount at Dec. 31, 2017	$ 3,658,127	$ 10,616	$ 161,067,538	$ (157,420,027)
Balance, Share at Dec. 31, 2017		10,615,724
Issuance of common stock in private placement, Amount	3,120,000	$ 1,300	3,118,700	0
Issuance of common stock in private placement, Share		1,300,000
Stock options exercised for cash, Amount	18,125	$ 10	18,115	0
Stock options exercised for cash, Share		10,416
Stock warrants exercised for cash, Amount	4,261,085	$ 1,447	4,259,638	0
Stock warrants exercised for cash, Share		1,446,881
Stock warrants cashless exercised, Amount	0	$ 118	(118)	0
Stock warrants cashless exercised, Share		118,425
Stock-based compensation, Amount	1,096,472	$ 133	1,096,339	0
Stock-based compensation, Share		132,825
Fair value of repriced warrants as inducement	0	$ 0	727,513	(727,513)
Net loss	(8,009,283)	0	0	(8,009,283)
Balance, Amount at Jun. 30, 2018	$ 4,144,526	$ 13,624	$ 170,287,725	$ (166,156,823)
Balance, Share at Jun. 30, 2018		13,624,271

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($)	6 Months Ended
	Jun. 30, 2018	Jun. 30, 2017
Cash Flows from Operating Activities:
Net loss	$ (8,009,283)	$ (4,313,262)
Reconciliation of net loss to net cash used in operating activities:
Changes in fair value of warrant liabilities	138,000	(4,500)
Stock-based compensation	1,096,472	647,387
Debt extinguishment gain	0	(492,365)
Changes in operating assets and liabilities:
Prepaid expenses and deposits	(57,566)	(109,032)
Accounts payable and accrued expenses	2,086,840	336,135
Net cash used in operating activities	(4,745,537)	(3,935,637)
Cash Flows from Financing Activities:
Proceeds from issuance of common stock and warrants in private placement, net of offering costs	3,120,000	5,408,343
Proceeds from exercise of stock warrants, net of offering costs	4,261,085	638,666
Proceeds from exercise of stock options	18,125	0
Net cash provided by financing activities	7,399,210	6,047,009
Net increase in cash	2,653,673	2,111,372
Cash at beginning of period	5,129,289	7,851,243
Cash at end of period	7,782,962	9,962,615
Supplemental schedule of non-cash financing activities:
Fair value of repriced warrants as inducement	727,513	622,042
Stock warrants cashless exercised	$ 118	$ 0

NATURE OF OPERATIONS

6 Months Ended

Jun. 30, 2018

Organization, Consolidation and Presentation of Financial Statements [Abstract]

NATURE OF OPERATIONS

Note 1: Nature of Operations

TapImmune Inc. (the “Company” or “we”), a Nevada corporation incorporated in 1991, is a biotechnology company focusing on immunotherapy specializing in the development of innovative peptide and gene-based immunotherapeutics and vaccines for the treatment of oncology. Unlike other vaccine technologies that narrowly address the initiation of an immune response, TapImmune's approach broadly stimulates the cellular immune system by enhancing the function of killer T-cells and T-helper cells and by restoring antigen presentation in tumor cells allowing their recognition by the immune system.

BASIS OF PRESENTATION

6 Months Ended

Jun. 30, 2018

Organization, Consolidation and Presentation of Financial Statements [Abstract]

BASIS OF PRESENTATION

NOTE 2: Basis of Presentation

The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with the accounting principles generally accepted in the United States of America (“U.S. GAAP”) for interim financial information and pursuant to the instructions to Form 10-Q and Article 8 of Regulation S-X of the Securities and Exchange Commission (“SEC”) and on the same basis as the Company prepares its annual audited consolidated financial statements. In the opinion of management, the accompanying unaudited condensed consolidated financial statements reflect all adjustments, consisting of normal recurring adjustments, considered necessary for a fair presentation of such interim results.

The results for the condensed consolidated statement of operations are not necessarily indicative of results to be expected for the year ending December 31, 2018 or for any future interim period. The condensed consolidated balance sheet at June 30, 2018 has been derived from unaudited financial statements; however, it does not include all of the information and notes required by U.S. GAAP for complete financial statements. The accompanying condensed consolidated financial statements should be read in conjunction with the consolidated financial statements for the year ended December 31, 2017, and notes thereto included in the Company’s annual report on Form 10-K filed on March 23, 2018.

LIQUIDITY AND FINANCIAL CONDITION

6 Months Ended

Jun. 30, 2018

Text Block [Abstract]

LIQUIDITY AND FINANCIAL CONDITION

NOTE 3: LIQUIDITY AND FINANCIAL CONDITION

The Company’s activities since inception have consisted principally of acquiring product and technology rights, raising capital, and performing research and development. Successful completion of the Company’s development programs and, ultimately, the attainment of profitable operations are dependent on future events, including, among other things, its ability to access potential markets; secure financing, develop a customer base; attract, retain and motivate qualified personnel; and develop strategic alliances and collaborations. From inception, the Company has been funded by a combination of equity and debt financings.

The Company expects to continue to incur substantial losses over the next several years during its development phase. To fully execute its business plan, the Company will need to complete certain research and development activities and clinical studies. Further, the Company’s product candidates will require regulatory approval prior to commercialization. These activities may span many years and require substantial expenditures to complete and may ultimately be unsuccessful. Any delays in completing these activities could adversely impact the Company. The Company plans to meet its capital requirements primarily through issuances of debt and equity securities and, in the longer term, revenue from product sales.

As of June 30, 2018, the Company had cash of approximately $7.8 million. Historically, the Company had net losses and negative cash flows from operations. Management intends to continue its research efforts and to finance operations of the Company through debt and/or equity financings. Management plans to seek additional debt and/or equity financing through private or public offerings. There can be no assurance that the Company will be successful in obtaining additional financing on favorable terms, or at all. The Company has no sources of revenue to provide incoming cash flows to sustain its future operations. The Company’s ability to pursue its planned business activities is dependent upon successful efforts to raise additional capital. These factors raise substantial doubt regarding the Company’s ability to continue as a going concern. The financial statements do not include any adjustments that might result from the outcome of these uncertainties.

SIGNIFICANT ACCOUNTING POLICIES

6 Months Ended

Jun. 30, 2018

Accounting Policies [Abstract]

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

Note 4: SIGNIFICANT ACCOUNTING POLICIES

There have been no material changes in the Company’s significant accounting policies to those previously disclosed in the Company’s annual report on Form 10-K, which was filed with the SEC on March 23, 2018.

New Accounting Pronouncement

From time to time, new accounting pronouncements are issued by the Financial Accounting Standards Board (“FASB”) or other standard setting bodies that we adopt as of the specified effective date. Unless otherwise discussed, we do not believe that the impact of recently issued standards that are not yet effective will have a material impact on our financial position or results of operations upon adoption.

Recent Accounting Pronouncements Adopted in the Year

Compensation-Stock Compensation

In May 2017, the FASB issued Accounting Standards Update (“ASU”) No. 2017-09, Compensation—Stock Compensation (Topic 718): Scope of Modification Accounting, which clarifies when to account for a change to the terms or conditions of a share-based payment award as a modification. Under the new guidance, modification accounting is required only if the fair value, the vesting conditions, or the classification of the award (as equity or liability) changes as a result of the change in terms or conditions. It is effective prospectively for the annual period beginning after December 15, 2017 and interim periods within that annual period. Early adoption is permitted. The Company adopted ASU 2017-09 on January 1, 2018; the adoption of ASU 2017-09 did not have a material impact on its financial condition or results of operations, as the Company has not had any modifications to share-based payment awards. However, if the Company does have a modification to an award in the future, it will follow the guidance in ASU 2017-09.

Revenue from Contracts with Customers

In May 2014, the FASB issued ASU No. 2014-09, “Revenue from Contracts with Customers (Topic 606)” (ASU 2014-09) as modified by ASU No. 2015-14, “Revenue from Contracts with Customers (Topic 606): Deferral of the Effective Date,” ASU 2016-08, “Revenue from Contracts with Customers (Topic 606): Principal versus Agent Considerations (Reporting Revenue Gross versus Net),” ASU No. 2016-10, “Revenue from Contracts with Customers (Topic 606): Identifying Performance Obligations and Licensing,” and ASU No. 2016-12, “Revenue from Contracts with Customers (Topic 606): Narrow-Scope Improvements and Practical Expedients.” The revenue recognition principle in ASU 2014-09 is that an entity should recognize revenue to depict the transfer of goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. In addition, new and enhanced disclosures will be required. Companies may adopt the new standard either using the full retrospective approach, a modified retrospective approach with practical expedients, or a cumulative effect upon adoption approach. The Company adopted the new standard effective January 1, 2018, using the modified retrospective approach. The only impact of the adoption of ASU 2014-09 was to reclassify the Company's grant income as revenue.

Recent Accounting Pronouncements Not Yet Adopted

Accounting for Certain Financial Instruments with Down Round Features

On July 13, 2017, the FASB has issued a two-part ASU, No. 2017-11, (i). Accounting for Certain Financial Instruments with Down Round Features and (ii) Replacement of the Indefinite Deferral for Mandatorily Redeemable Financial Instruments of Certain Nonpublic Entities and Certain Mandatorily Redeemable Noncontrolling Interests With a Scope Exception.

The ASU is effective for public business entities for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2018 and the interim periods within that annual period. Early adoption is permitted. The Company will be evaluating the impact of adopting this standard on the consolidated financial statements and disclosures.

Improvements to Nonemployee Share-Based Payment Accounting

In June 2018, the FASB issued ASU 2018-07 “Improvements to Nonemployee Share-Based Payment Accounting”, which simplifies the accounting for share-based payments granted to nonemployees for goods and services. Under the ASU, most of the guidance on such payments to nonemployees would be aligned with the requirements for share-based payments granted to employees. The amendments are effective for fiscal years beginning after December 15, 2019, and interim periods within fiscal years beginning after December 15, 2020. Early adoption is permitted, but no earlier than an entity’s adoption date of Topic 606. The Company is currently evaluating the impact of the new standard on its consolidated financial statements.

NET LOSS PER SHARE APPLICABLE TO COMMON SHAREHOLDER

6 Months Ended

Jun. 30, 2018

Noncontrolling Interest [Abstract]

NET LOSS PER SHARE APPLICABLE TO COMMON SHAREHOLDER

Note 5: NET LOSS PER SHARE APPLICABLE TO COMMON SHAREHOLDER

Basic loss per common share is computed by dividing net loss by the weighted average number of common shares outstanding during the reporting period. Diluted loss per common share is computed similarly to basic loss per common share except that it reflects the potential dilution that could occur if dilutive securities or other obligations to issue common stock were exercised or converted into common stock.

The following table sets forth the computation of net loss per share:

	Six Months Ended						Six Months Ended
	June 30,						June 30,
	2018			2017			2018			2017
Numerator:
Net loss	$	(4,812,797	)	$	(1,893,377	)	$	(8,009,283	)	$	(4,313,262	)

Denominator:
Weighted average common shares outstanding		11,838,371			8,576,634			11,233,755			8,503,521

Net loss per share data:
Basic and Diluted	$	(0.41	)	$	(0.22	)	$	(0.71	)	$	(0.51	)

The following securities, rounded to the thousand, were not included in the diluted net loss per share calculation because their effect was anti-dilutive for the periods presented:

	Six Months Ended
	June 30,
	2018		2017
Common stock options		439,000		455,000
Common stock purchase warrants		4,871,000		6,544,000
Potentially dilutive securities		5,310,000		6,999,000

WARRANT LIABILITY AND FAIR VALUE MEASUREMENTS

6 Months Ended

Jun. 30, 2018

Derivatives and Fair Value [Abstract]

WARRANT LIABILITY AND FAIR VALUE MEASUREMENTS

NOTE 6: WARRANT LIABILITY AND FAIR VALUE MEASUREMENTS

A summary of quantitative information with respect to valuation methodology and significant unobservable inputs used for the Company’s common stock purchase warrants that are categorized within Level 3 of the fair value hierarchy for the six months ended June 30, 2018 and 2017 is as follows:

	June 30,			June 30,
	2018			2017
Stock price	$	9.43		$	3.88
Exercise price	$	8.67		$	1.20
Contractual term (years)		1.32			1.03
Volatility (annual)		83	%		78	%
Risk-free rate		1	%		1	%
Dividend yield (per share)		0	%		0	%

The foregoing assumptions are reviewed quarterly and are subject to change based primarily on management’s assessment of the probability of the events described occurring. Accordingly, changes to these assessments could materially affect the valuations.

Financial Liabilities Measured at Fair Value on a Recurring Basis

Financial liabilities measured at fair value on a recurring basis are summarized below and disclosed on the balance sheet under Warrant liability:

Fair value measured at June 30, 2018

Quoted prices in active

Significant other

Significant

markets

observable inputs

unobservable inputs

Fair value at

(Level 1)

(Level 2)

(Level 3)

June 30, 2018

Warrant liability

147,000

Fair value measured at December 31, 2017

Quoted prices in active

Significant other

Significant

markets

observable inputs

unobservable inputs

Fair value at

(Level 1)

(Level 2)

(Level 3)

December 31, 2017

Warrant liability

9,000

The fair value accounting standards define fair value as the amount that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants. As such, fair value is determined based upon assumptions that market participants would use in pricing an asset or liability. Fair value measurements are rated on a three-tier hierarchy as follows:

Level 1 inputs: Quoted prices (unadjusted) for identical assets or liabilities in active markets;

Level 2 inputs: Inputs, other than quoted prices included in Level 1, that are observable either directly or indirectly; and

Level 3 inputs: Unobservable inputs for which there is little or no market data, which require the reporting entity to develop its own assumptions.

There were no transfers between Level 1, 2 or 3 during the six months ended June 30, 2018.

The following table presents changes in Level 3 liabilities measured at fair value for the six months ended June 30, 2018:

	Warrant
	Liability
Balance - December 31, 2017	$	9,000
Change in fair value of warrant liability		138,000
Balance – June 30, 2018	$	147,000

STOCKHOLDERS' EQUITY

6 Months Ended

Jun. 30, 2018

Stockholders' Equity Note [Abstract]

STOCKHOLDERS' EQUITY

Note 7: STOCKHOLDERS’ EQUITY

2018 Common Stock Transactions

Common Stock Purchase Agreement

On May 14, 2018, the Company’s largest stockholder Eastern Capital Limited entered into a Common Stock Purchase Agreement with the Company pursuant to which it purchased 1,300,000 shares of common stock at a price per share of $2.40 providing gross proceeds to the Company of $3.12 million.

Exercise and Repricing of Warrants Held by Existing Institutional Investors

On May 14, 2018, certain institutional holders of outstanding warrants entered into Warrant Exercise Agreements with the Company that provide for an amendment to the exercise price of the warrants being exercised at $2.50 per share. Upon closing of the Warrant Exercise Agreements, such institutional holders immediately exercised warrants for 782,505 shares of common stock providing aggregate proceeds to the Company of approximately $2.0 million.

The fair value relating to the modification of exercise prices on the repriced and exercised warrants was treated as deemed dividend on the statement of stockholders’ equity of $728,000.

A weighted average summary of quantitative information with respect to valuation methodology and significant unobservable inputs used for the Company’s common stock purchase warrants that are included in the modification is as follows:

	Weighted Average Inputs
	Before			After
	Modification			Modification
Exercise price	$	9.93		$	2.50
Contractual term (years)		2.37			2.37
Volatility (annual)		79	%		79	%
Risk-free rate		1.5	%		1.5	%
Dividend yield (per share)		0	%		0	%

Exercise of Stock Warrants

During June 2018, shareholders exercised 782,800 shares of common stock pursuant to stock warrants providing aggregate proceeds to the Company of approximately $2.3 million.

118,425

of the stock warrants exercised were exercised on a cashless basis, resulting in a cancellation of 83,130 stock warrants.

Exercise of Stock Options

In January 2018, 10,416 shares of common stock were issued pursuant to stock option exercises at an exercise price equal to $1.74 per share.

Consulting Arrangements

During the six months ended June 30, 2018, the Company issued 132,825 shares of common stock as part of consulting agreements. The fair value of the common stock of approximately $644,000 was recognized as stock-based compensation, $563,000 in general and administrative expenses and $81,000 in research and development expenses.

Share Purchase Warrants

A summary of the Company’s share purchase warrants as of June 30, 2018 and changes during the period is presented below:

						Weighted Average
	Number of			Weighted Average		Remaining Contractual		Total Intrinsic
	Warrants			Exercise Price		Life (in years)		Value
Balance - January 1, 2018		6,520,000		$	6.11		3.16	$	1,739,000
Issued		-			-		-		-
Cashless exercised		(118,000	)		4.01		-		-
Exercised for cash		(1,447,000	)		2.95		-		-
Expired or Cancelled		(84,000	)		4.01		-		-
Balance - June 30, 2018		4,871,000		$	5.94		2.76	$	20,417,000

STOCK-BASED COMPENSATION

6 Months Ended

Jun. 30, 2018

Disclosure of Compensation Related Costs, Share-based Payments [Abstract]

STOCK-BASED COMPENSATION

Note 8: STOCK-BASED COMPENSATION

The Company recorded approximately $960,000 and $271,000 of stock-based compensation expense for the three months ended June 30, 2018 and 2017, respectively. The Company recorded approximately $1,096,000 and $647,000 of stock-based compensation expense for the six months ended June 30, 2018 and 2017, respectively.

At June 30, 2018, the total stock-based compensation cost related to unvested awards not yet recognized was $159,000. The expected weighted average period compensation costs to be recognized was 0.48 years. Future option grants will impact the compensation expense recognized.

$596,000 and $364,000 of stock-based compensation expenses for the three months ended June 30, 2018 were included in general and administrative expenses and research and development expenses, respectively, on the condensed consolidated statements of operations.

$629,000 and $467,000 of stock-based compensation expenses for the six months ended June 30, 2018 were included in general and administrative expenses and research and development expenses, respectively, on the condensed consolidated statements of operations.

GRANT INCOME

6 Months Ended

Jun. 30, 2018

Grant Income [Abstract]

GRANT INCOME

Note 9:

grant income

During the six months ended June 30, 2018, the Company received $0.2 million of a grant awarded to Mayo Foundation from the U.S. Department of Defense for the Phase II Clinical Trial of TPIV200. The grant compensated the Company for clinical supplies manufactured and provided by the Company for the clinical study. In accordance with Accounting Standards Update No. 2014-09, “Revenue from Contracts with Customers (Topic 606)” issued by the Financial Accounting Standards Board, the Company recorded the $0.2 million of grant income as revenue.

SIGNIFICANT ACCOUNTING POLICIES (Policies)

6 Months Ended

Jun. 30, 2018

Accounting Policies [Abstract]

New Accounting Pronouncements

New Accounting Pronouncement

Recent Accounting Pronouncements Adopted in the Year

Compensation-Stock Compensation

Revenue from Contracts with Customers

Recent Accounting Pronouncements Not Yet Adopted

Accounting for Certain Financial Instruments with Down Round Features

Improvements to Nonemployee Share-Based Payment Accounting

NET LOSS PER SHARE APPLICABLE TO COMMON SHAREHOLDER (Tables)

6 Months Ended

Jun. 30, 2018

Noncontrolling Interest [Abstract]

Schedule of Earnings Per Share, Basic and Diluted

The following table sets forth the computation of net loss per share:

	Six Months Ended						Six Months Ended
	June 30,						June 30,
	2018			2017			2018			2017
Numerator:
Net loss	$	(4,812,797	)	$	(1,893,377	)	$	(8,009,283	)	$	(4,313,262	)

Denominator:
Weighted average common shares outstanding		11,838,371			8,576,634			11,233,755			8,503,521

Net loss per share data:
Basic and Diluted	$	(0.41	)	$	(0.22	)	$	(0.71	)	$	(0.51	)

Net Loss Per Share

The following securities, rounded to the thousand, were not included in the diluted net loss per share calculation because their effect was anti-dilutive for the periods presented:

	Six Months Ended
	June 30,
	2018		2017
Common stock options		439,000		455,000
Common stock purchase warrants		4,871,000		6,544,000
Potentially dilutive securities		5,310,000		6,999,000

WARRANT LIABILITY AND FAIR VALUE MEASUREMENTS (Tables)

6 Months Ended

Jun. 30, 2018

Derivatives and Fair Value [Abstract]

Valuation Methodology

	June 30,			June 30,
	2018			2017
Stock price	$	9.43		$	3.88
Exercise price	$	8.67		$	1.20
Contractual term (years)		1.32			1.03
Volatility (annual)		83	%		78	%
Risk-free rate		1	%		1	%
Dividend yield (per share)		0	%		0	%

Financial Assets and Liabilities Measured at Fair Value on a Recurring Basis

Financial liabilities measured at fair value on a recurring basis are summarized below and disclosed on the balance sheet under Warrant liability:

Fair value measured at June 30, 2018

Quoted prices in active

Significant other

Significant

markets

observable inputs

unobservable inputs

Fair value at

(Level 1)

(Level 2)

(Level 3)

June 30, 2018

Warrant liability

147,000

Fair value measured at December 31, 2017

Quoted prices in active

Significant other

Significant

markets

observable inputs

unobservable inputs

Fair value at

(Level 1)

(Level 2)

(Level 3)

December 31, 2017

Warrant liability

9,000

Schedule of Changes in Level 3 Liabilities Measured at Fair Value

The following table presents changes in Level 3 liabilities measured at fair value for the six months ended June 30, 2018:

	Warrant
	Liability
Balance - December 31, 2017	$	9,000
Change in fair value of warrant liability		138,000
Balance – June 30, 2018	$	147,000

STOCKHOLDERS' EQUITY (Tables)

6 Months Ended

Jun. 30, 2018

Schedule of weighted average valuation methodology

	Weighted Average Inputs
	Before			After
	Modification			Modification
Exercise price	$	9.93		$	2.50
Contractual term (years)		2.37			2.37
Volatility (annual)		79	%		79	%
Risk-free rate		1.5	%		1.5	%
Dividend yield (per share)		0	%		0	%

Schedule of share purchase warrants

A summary of the Company’s share purchase warrants as of June 30, 2018 and changes during the period is presented below:

						Weighted Average
	Number of			Weighted Average		Remaining Contractual		Total Intrinsic
	Warrants			Exercise Price		Life (in years)		Value
Balance - January 1, 2018		6,520,000		$	6.11		3.16	$	1,739,000
Issued		-			-		-		-
Cashless exercised		(118,000	)		4.01		-		-
Exercised for cash		(1,447,000	)		2.95		-		-
Expired or Cancelled		(84,000	)		4.01		-		-
Balance - June 30, 2018		4,871,000		$	5.94		2.76	$	20,417,000

LIQUIDITY AND FINANCIAL CONDITION - Additional Information (Detail) $ in Millions	Jun. 30, 2018 USD ($)
Cash and Cash Equivalents [Line Items]
Cash and cash equivalents	$ 7.8

NET LOSS PER SHARE APPLICABLE TO COMMON SHAREHOLDER - Computation of income (loss) per share (Detail) - USD ($)	3 Months Ended		6 Months Ended
	Jun. 30, 2018	Jun. 30, 2017	Jun. 30, 2018	Jun. 30, 2017
Numerator:
Net loss	$ (4,812,797)	$ (1,893,377)	$ (8,009,283)	$ (4,313,262)
Denominator:
Weighted average common shares outstanding	11,838,371	8,576,634	11,233,755	8,503,521
Net loss per share data:
Basic and Diluted	$ (0.41)	$ (0.22)	$ (0.71)	$ (0.51)

- Definition

The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.

+ References + Details

NET LOSS PER SHARE APPLICABLE TO COMMON SHAREHOLDER - Potentially Dilutive Securities (Detail) - shares	6 Months Ended
	Jun. 30, 2018	Jun. 30, 2017
Common stock options	439,000	455,000
Common stock purchase warrants	4,871,000	6,544,000
Potentially dilutive securities	5,310,000	6,999,000

WARRANT LIABILITY AND FAIR VALUE MEASUREMENTS - Conversion Option - Valuation Methodology (Detail) - Share Purchase Warrants [Member]	Jun. 30, 2018 $ / shares	Jun. 30, 2017 $ / shares
Measurement Input, Share Price [Member]
Fair Value Measurements, Recurring and Nonrecurring, Valuation Techniques [Line Items]
Stock price	$ 9.43	$ 3.88
Measurement Input, Exercise Price [Member]
Fair Value Measurements, Recurring and Nonrecurring, Valuation Techniques [Line Items]
Warrants and Rights Outstanding, Measurement Input	8.67	1.20
Measurement Input, Expected Term [Member]
Fair Value Measurements, Recurring and Nonrecurring, Valuation Techniques [Line Items]
Warrants and Rights Outstanding, Term	1 year 3 months 25 days	1 year 11 days
Measurement Input, Price Volatility [Member]
Fair Value Measurements, Recurring and Nonrecurring, Valuation Techniques [Line Items]
Warrants and Rights Outstanding, Measurement Input	83	78
Measurement Input, Risk Free Interest Rate [Member]
Fair Value Measurements, Recurring and Nonrecurring, Valuation Techniques [Line Items]
Warrants and Rights Outstanding, Measurement Input	1	1
Measurement Input, Expected Dividend Rate [Member]
Fair Value Measurements, Recurring and Nonrecurring, Valuation Techniques [Line Items]
Warrants and Rights Outstanding, Measurement Input	0	0

WARRANT LIABILITY AND FAIR VALUE MEASUREMENTS - Conversion Option - Financial Assets and Liabilities Measured at Fair Value on a Recurring Basis (Detail) - USD ($)	Jun. 30, 2018	Dec. 31, 2017
Quoted prices in active markets (Level 1)
Derivatives, Fair Value [Line Items]
Warrant liability	$ 0	$ 0
Significant other observable inputs (Level 2)
Derivatives, Fair Value [Line Items]
Warrant liability	0	0
Significant other unobservable inputs (Level 3)
Derivatives, Fair Value [Line Items]
Warrant liability	147,000	9,000
Fair Value [Member]
Derivatives, Fair Value [Line Items]
Warrant liability	$ 147,000	$ 9,000

WARRANT LIABILITY AND FAIR VALUE MEASUREMENTS - Conversion Option - Schedule of Changes in Level 3 Liabilities Measured at Fair Value (Detail)	6 Months Ended
	Jun. 30, 2018 USD ($)
Class of Warrant or Right [Line Items]
Balance	$ 9,000
Change in fair value of warrant liability	138,000
Balance	$ 147,000

STOCKHOLDERS' EQUITY - Weighted average summary of quantitative information (Detail) - Share Purchase Warrants [Member]	Jun. 30, 2018	Jun. 30, 2017
Measurement Input, Exercise Price [Member]
Fair Value Measurements, Recurring and Nonrecurring, Valuation Techniques [Line Items]
Warrants and Rights Outstanding, Measurement Input	8.67	1.20
Measurement Input, Expected Term [Member]
Fair Value Measurements, Recurring and Nonrecurring, Valuation Techniques [Line Items]
Warrants and Rights Outstanding, Term	1 year 3 months 25 days	1 year 11 days
Measurement Input, Price Volatility [Member]
Fair Value Measurements, Recurring and Nonrecurring, Valuation Techniques [Line Items]
Warrants and Rights Outstanding, Measurement Input	83	78
Measurement Input, Risk Free Interest Rate [Member]
Fair Value Measurements, Recurring and Nonrecurring, Valuation Techniques [Line Items]
Warrants and Rights Outstanding, Measurement Input	1	1
Measurement Input, Expected Dividend Rate [Member]
Fair Value Measurements, Recurring and Nonrecurring, Valuation Techniques [Line Items]
Warrants and Rights Outstanding, Measurement Input	0	0
Weighted Average Inputs Before Modification [Member] \| Measurement Input, Exercise Price [Member]
Fair Value Measurements, Recurring and Nonrecurring, Valuation Techniques [Line Items]
Warrants and Rights Outstanding, Measurement Input	9.93
Weighted Average Inputs Before Modification [Member] \| Measurement Input, Expected Term [Member]
Fair Value Measurements, Recurring and Nonrecurring, Valuation Techniques [Line Items]
Warrants and Rights Outstanding, Term	2 years 4 months 13 days
Weighted Average Inputs Before Modification [Member] \| Measurement Input, Price Volatility [Member]
Fair Value Measurements, Recurring and Nonrecurring, Valuation Techniques [Line Items]
Warrants and Rights Outstanding, Measurement Input	79
Weighted Average Inputs Before Modification [Member] \| Measurement Input, Risk Free Interest Rate [Member]
Fair Value Measurements, Recurring and Nonrecurring, Valuation Techniques [Line Items]
Warrants and Rights Outstanding, Measurement Input	1.5
Weighted Average Inputs Before Modification [Member] \| Measurement Input, Expected Dividend Rate [Member]
Fair Value Measurements, Recurring and Nonrecurring, Valuation Techniques [Line Items]
Warrants and Rights Outstanding, Measurement Input	0
Weighted Average Inputs After Modification [Member] \| Measurement Input, Exercise Price [Member]
Fair Value Measurements, Recurring and Nonrecurring, Valuation Techniques [Line Items]
Warrants and Rights Outstanding, Measurement Input		2.50
Weighted Average Inputs After Modification [Member] \| Measurement Input, Expected Term [Member]
Fair Value Measurements, Recurring and Nonrecurring, Valuation Techniques [Line Items]
Warrants and Rights Outstanding, Term		2 years 4 months 13 days
Weighted Average Inputs After Modification [Member] \| Measurement Input, Price Volatility [Member]
Fair Value Measurements, Recurring and Nonrecurring, Valuation Techniques [Line Items]
Warrants and Rights Outstanding, Measurement Input		79
Weighted Average Inputs After Modification [Member] \| Measurement Input, Risk Free Interest Rate [Member]
Fair Value Measurements, Recurring and Nonrecurring, Valuation Techniques [Line Items]
Warrants and Rights Outstanding, Measurement Input		1.5
Weighted Average Inputs After Modification [Member] \| Measurement Input, Expected Dividend Rate [Member]
Fair Value Measurements, Recurring and Nonrecurring, Valuation Techniques [Line Items]
Warrants and Rights Outstanding, Measurement Input		0

STOCKHOLDERS' EQUITY- Summary of the Company's share purchase warrants (Detail) - USD ($)	6 Months Ended	12 Months Ended
	Jun. 30, 2018	Dec. 31, 2017
Number of Warrants, Beginning balance	6,520,000
Number of Warrants, Issued	0
Number of Warrant of Cashless exercised	(118,000)
Number of Warrant Exercised for cash	(1,447,000)
Number of Warrant Expired or Cancelled	(84,000)
Number of Warrants, Ending balance	4,871,000	6,520,000
Weighted Average Exercise Price, Beginning Balance	$ 6.11
Weighted Average Exercise Price, Issued	0
Weighted Average Exercise Price Cashless exercised	4.01
Weighted Average Exercise Price, Exercised for cash	2.95
Weighted Average Exercise Price Expired or Cancelled	4.01
Weighted Average Exercise Price, Ending Balance	$ 5.94	$ 6.11
Weighted Average Remaining Contractual Life, Outstanding (in years)	2 years 9 months 4 days	3 years 1 month 28 days
Total Intrinsic Value	$ 20,417,000	$ 1,739,000

STOCKHOLDERS' EQUITY - Additional Information (Detail) - USD ($)		1 Months Ended	3 Months Ended		6 Months Ended
	May 14, 2018	Jan. 31, 2018	Jun. 30, 2018	Jun. 30, 2017	Jun. 30, 2018	Jun. 30, 2017
Common Stock Capital Shares Reserved For Future Issuance [Line Items]
Stock Issued During Period, Shares, New Issues	1,300,000
Shares Issued, Price Per Share	$ 2.50
Stock Issued During Period, Value, New Issues	$ 3,120,000
Class of Warrant or Right, Number of Securities Called by Warrants or Rights	782,505		782,800		782,800
Proceeds from Warrant Exercises	$ 2,000,000				$ 4,261,085	$ 638,666
Exercise Of Warrants Amount					4,261,085
Non Cash Excercise Of Warrants Amount					$ 118	0
Number Of Warrant Expired or Cancelled					(84,000)
Research and Development Expense			$ 1,826,837	$ 1,202,725	$ 3,426,387	$ 2,191,817
Consulting Arrangements [Member]
Common Stock Capital Shares Reserved For Future Issuance [Line Items]
Allocated Share-based Compensation Expense					132,825
Selling, General and Administrative Expense					644,000
Research and Development Expense					$ 563,000
Stock Issued During Period, Shares, Issued for Services					81,000
Warrant [Member]
Common Stock Capital Shares Reserved For Future Issuance [Line Items]
Exercise Of Warrants Amount					$ 728,000
Eastern Capital Limited [Member]
Common Stock Capital Shares Reserved For Future Issuance [Line Items]
Shares Issued, Price Per Share	$ 2.40
Common Stock [Member]
Common Stock Capital Shares Reserved For Future Issuance [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period		10,416			10,416
Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price		$ 1.74
Exercise Of Warrants Amount					$ 1,447

STOCK-BASED COMPENSATION - Additional Information (Detail) - USD ($)	3 Months Ended		6 Months Ended
	Jun. 30, 2018	Jun. 30, 2017	Jun. 30, 2018	Jun. 30, 2017
Share-based Compensation	$ 960,000	$ 271,000	$ 1,096,472	$ 647,387
Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized	159,000		$ 159,000
Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized, Period for Recognition			5 months 23 days
Selling, General and Administrative Expenses [Member]
Share-based Compensation	364,000		$ 467,000
Research and Development Expense [Member]
Share-based Compensation	$ 596,000		$ 629,000

GRANT INCOME - Additional Information (Detail) - Grant [Member] - USD ($)	3 Months Ended		6 Months Ended
	Jun. 30, 2018	Jun. 30, 2017	Jun. 30, 2018	Jun. 30, 2017
Revenue from Contract with Customer, Including Assessed Tax	$ 205,994	$ 0	$ 205,994	$ 0
Accounting Standards Update 2014-09 [Member]
Revenue from Contract with Customer, Including Assessed Tax			$ 200,000